SynthyraEliminating Drug
Attrition Before
The Clinic.
The leader in proteome-scale protein interaction prediction. We provide a predictive reality check for generative AI workflows, flagging human toxicity at atomic precision.
Generative Hallucinations
Validated Candidates
Filter AI Leads.
Generative models are fast, but they require validation. We screen your AI leads against billions of potential interactions in minutes.
Solving the $60 Billion Loss Problem in Clinical Trials.
Prevent Phase I Failure
Redirect safety budgets to prevent late-stage failures by catching adverse events before they enter the clinic.
The Interactome Map
Clinical trial failure isn't random; it's a network effect. We see what animal models can't by screening the full human interactome.
IP Protection
Move only your safest, most specific binders into the pipeline, preserving capital and patent value for viable assets.
Stop Testing Failures.
Why waste wetlab cycles on dead-end leads?
Standard MD
Not IND ReadyTraditional MD runs blindly on unfiltered candidates. It wastes weeks of compute time simulating low-probability binders that fail due to predicted clinical adverse events or poor affinity.
MD + Synthyra PreCheck®
Higher Phase 1 SuccessSynthyra triages your pipeline first. By running MD only on candidates pre-validated against the full human proteome, you ensure every simulation cycle is spent on a high-probability binder.
Accelerated Pipeline Validation
While traditional methods iterate for years, Synthyra triages billions of interactions upfront, moving only validated binders to the lab.
Standard Discovery Pipeline
High Attrition & Iteration Cycles
Years of trial and error before clinical entry.
Synthyra Driven Pipeline
← Years of optimization logic compressed into one screen.
Smart filtering eliminates toxic assets before wet lab synthesis.
The Business Case for Safety First
40%
The Phase I Failure Blind Spot
33-40% of drugs fail in Phase 1 due to safety issues that animal models cannot predict. We close this gap.
$50M
Saved in Phase II
Redirect 1-2% of inefficient safety budgets to Synthyra to avoid late-stage failures, saving millions in sunk costs.
Ready to verify your pipeline?
Stop betting on probability. Start screening against the full human proteome. Secure your spot in our triage pilot program today.
Academic Spinout
Synthyra is a proud spinout of the Gleghorn Lab at the University of Delaware with ongoing pilots in six leading academic labs with focuses ranging from Cancer Therapeutics to Microbiome Health.
Clinical Validation
Synthyra has developed a variant of Cetuximab, a multi-billion dollar Cancer therapeutic, with 87% stronger binding affinity (630 pM Kd). We have computationally validated billions of proteins.
Community Trusted
Trusted by the open-source community with over millions and millions of downloads.